Inhibition of STAT3 signaling may improve survival in those with H3.3G34R/V mutant gliomas, animal studies suggest.
In cell and mouse models, metformin suppressed tumor growth in group A posterior fossa ependymomas.
A common mutation in gliomas sensitizes them to immunotherapy, a finding which researchers believe could have broader therapeutic implications for all glioma patients.
A combination approach, which included metabolic reprogramming and immunotherapy, led to complete tumor regression in 60% of study mice.
Researchers have demonstrated that a new liquid biopsy approach overcomes traditional barriers to quickly and efficiently diagnose and monitor high-grade gliomas.